Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. develops a weight-loss platform centered on the Allurion Program, which combines the FDA PMA approved Allurion Gastric Balloon System featuring the Allurion Smart Capsule with a Virtual Care Suite that includes the Allurion Mobile App, Iris AI, Allurion Insights and the Allurion Connected Scale.
Company news centers on U.S. commercialization of the Allurion Smart Capsule, FDA regulatory status, provider training and commercial account onboarding, obesity-care partnerships and use of the program alongside GLP-1 therapies. Updates also cover preliminary operating results, balance-sheet and warrant-related capital actions, and listing-compliance matters involving Allurion common stock and warrants.
Allurion Technologies (NYSE: ALUR) has released new data demonstrating long-term effectiveness of the Allurion Program for weight loss. Two significant studies revealed impressive results:
The first study of 522 patients showed an average weight loss of 32 pounds (14.4kg) after four months, with 95% weight maintenance one year after balloon removal. The second study involving 497 patients demonstrated a 14.3% total body weight reduction, with 86% of patients maintaining weight loss after one year.
The company's AI-powered Virtual Care Suite supports sustainable weight loss through behavioral change, reinforcing Allurion's commitment to metabolically healthy weight loss solutions.
Allurion Technologies (NYSE:ALUR) has announced a strategic distribution partnership with Minogue Medical Inc. in Canada to advance metabolically healthy weight loss solutions. The partnership leverages Minogue Medical's 40-year experience and extensive network of dietitians, bariatric surgeons, and endoscopic specialists across Canada.
The collaboration aims to increase access to the Allurion Program combined with GLP-1 therapy, focusing on sustainable weight loss while maintaining muscle mass. Minogue Medical's established infrastructure and expertise in bariatric and obesity care will help implement Allurion's approach through a medically supervised, evidence-based framework.
Allurion Technologies (NYSE: ALUR) has announced the submission of its final Pre-Market Approval (PMA) module to the FDA, along with additional analyses from its AUDACITY Study for its weight loss balloon device. The pivotal study has successfully met both co-primary endpoints after new analyses.
The study involved 550 subjects randomized 1:1 between treatment and control groups. Using updated imputation methods, the treatment group showed a 4.34% mean difference in weight loss at 48 weeks with a 3.14% super-superiority margin (p = .0142), exceeding the pre-specified 3% margin. At 40 weeks, the difference was even more pronounced at 4.90% with a 3.75% margin (p = .0006).
Allurion Technologies (NYSE: ALUR), a company focused on metabolically healthy weight loss, announced that its Founder and CEO, Dr. Shantanu Gaur, will deliver a presentation at the Jefferies Global Healthcare Conference in New York. The presentation is scheduled for June 4 at 3:45 p.m. ET. Interested parties can access the webcast through the Events & Presentations section of Allurion's investor relations website.
Allurion Technologies (NYSE: ALUR) presented significant clinical results at the SOFFCO.MM meeting in France, showcasing the effectiveness of their Allurion Program for weight loss. The study of 1,962 French patients demonstrated remarkable outcomes after four months:
- 12.2% average reduction in total body weight
- 6.6% increase in muscle mass percentage
- 11% decrease in fat mass
- 12.2% reduction in visceral fat index
Additionally, the company announced the resumption of shipments to France, with patient treatments expected to restart next month, marking their return to the French market with a focus on metabolically healthy weight loss.
- Patients using GLP-1s with the Virtual Care Suite showed a 6.1% increase in lean body mass and 6.4% increase in muscle mass
- Combination therapy of Allurion Balloon with semaglutide achieved 21.2% body weight reduction, comparable to bariatric surgery outcomes
- The Allurion Program without GLP-1s demonstrated 12.4% weight reduction and 9.8% muscle mass increase in 2,000 patients
The studies suggest that Allurion's AI-driven behavioral support may help maintain muscle mass during GLP-1 therapy, while combination treatments could offer alternatives to bariatric surgery for severe obesity cases.
Allurion Technologies (NYSE: ALUR), a company focused on obesity treatment, has scheduled its first quarter 2025 financial results announcement for May 14, 2025. The company will host a conference call and webcast at 8:30 AM ET on the same day to discuss the results and provide a business update.
Participants can join via phone by dialing (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. The webcast will be available in the Events section of Allurion's Investor Relations website. A replay will be accessible by phone at (800) 770-2030 using Access Code 1905455, and the archived webcast will remain available on the company's website.
Allurion Technologies (NYSE: ALUR) has announced the postponement of its Special Meeting of Stockholders from April 4, 2025, to Thursday, April 10, 2025, at 12:00 p.m. (Eastern Time). The virtual meeting will be held via live audio webcast.
The postponement aims to allow additional time for proxy solicitation and provide stockholders more time to vote. The record date remains unchanged at March 14, 2025. Previously cast votes will remain valid unless stockholders choose to change or revoke them.
The Company's Board of Directors unanimously recommends voting FOR the proposals outlined in the Definitive Proxy Statement filed on March 24, 2025. Stockholders can access detailed information and voting instructions through the SEC website or Allurion's investor relations page.